Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Mary Thomas
Eligibility
Inclusion criteria
Inclusion criteria: Those who give informed written consent, patients who received anthracycline based chemotherapy, patients aged more than 18 years diagnosed with breast cancer, ASA I and II.
Exclusion criteria
Exclusion criteria: Those who are unwilling to participate, those with left ventricular ejection fraction less than 50 %, those who received Trastuzumab therapy and anti HER2 positive therapy, those unwilling to participate, those with pre existing heart disease, ASA III and IV
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To identify the incidence of subclinical cardiotoxicity, to assess longitudinal changes in myocardial function, association between echocardiographic parameters and intraoperative hypotension, and development of risk stratification model.Timepoint: Pre chemotherapy, post chemotherapy[ pre surgery], at 6 months and 12 months after surgery. | — |
Primary
| Measure | Time frame |
|---|---|
| Early detection of anthracycline induced myocardial dysfunction using echocardiographic strain indices and myocardial work compared with LVEF.Timepoint: Pre chemotherapy, post chemotherapy[ pre surgery], at 6 months and 12 months after surgery. | — |
Countries
India
Contacts
Public ContactMary Thomas
Junior resident, Department of Anaesthesiology
Outcome results
None listed